Urovant Collaboration, Sunovion Pharmaceuticals Sumitovant Biopharma Announces

Sumitovant Biopharma announced Urovant Sciences has entered into an exclusive three-year distribution agreement with Sunovion to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. All of the companies are subsidiaries of Sumitomo Dainippon Pharma.

The co-promotion agreement will enable Urovant to leverage Sunovion’s commercial infrastructure to increase efficiency of the planned launch of vibegron. The agreement covers services such as account management, contract operations, third party logistics and trade and retail distribution.

“Our affiliation with Sunovion through the Sumitomo Dainippon Pharma family of companies allows us to capitalize on the expertise and scale of Sunovion’s operational infrastructure,” said Kenton Stewart, SVP of Market Access of Urovant Sciences. “Through our combined efforts, we will accelerate preparations for our anticipated launch of vibegron in the U.S. market.”

“We are pleased to enter into this relationship with Urovant,” said Thomas Gibbs, SVP and Chief Commercial Officer of Sunovion. “This agreement will enable Urovant to access Sunovion’s well-established commercial capabilities as together we prepare for the launch of this important investigational medicine.”